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Purpose: To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing monopolar 
transurethral resection of the prostate (MTURP) and photoselective vaporization of the prostate (PVP) in order to provide the most 
up-to-date and reliable recommendations possible. 
Materials and Methods: Relevant RCTs were identified from electronic databases for meta-analysis of the surgical outcomes and 
complications of MTURP and PVP. Meta-analytical comparisons were made using qualitative and quantitative syntheses. The 
outcome variables are presented as odds ratios with 95% confidence intervals (CIs). 
Results: In total, 11 articles were included in this comparative analysis of PVP versus MTURP. Most of the recently published studies 
exhibited low risk in terms of quality assessment. MTURP was superior to PVP regarding operative time; however, with regard to 
catheterization and hospitalization time, the mean differences were −1.39 (95% CI=−1.83∼−0.95, p＜0.001) and −2.21 (95% 
CI=−2.73∼−1.69, p＜0.001), respectively, in favor of PVP. PVP was superior to MTURP with regard to transfusion rate and clot 
retention, but no statistically significant differences were found with regard to acute urinary retention and urinary tract infection. The 
long-term complications of bladder neck contracture and urethral stricture showed no statistically significant differences between 
PVP and MTURP. Long-term functional outcomes, including the International Prostate Symptom Score and maximum flow rate, 
likewise did not display statistically significant differences between PVP and MTURP. 
Conclusions: Based on our findings, we believe that PVP should be considered as an alternative surgical procedure for treating 
male lower urinary tract symptoms secondary to benign prostatic hyperplasia.
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INTRODUCTION
Male lower urinary tract symptoms (LUTS) are one of 
the most common clinical symptoms encountered in adult 
men, and have a major impact on quality of life [1]. Male 
LUTS are commonly due to bladder outlet obstruction sec-
ondary to benign prostatic hyperplasia (BPH) [2]. In such 
patients, medical treatments, including alpha-blockers, 
5-alpha-reductase inhibitors, muscarinic receptor antago-
nists, and low-dose tadalafil, are preferred, but surgery is 
an option for patients with bothersome LUTS due to be-
nign prostatic obstruction (BPO) who do not desire to un-
dergo medical treatment, in cases where medication does 
not prove efficacious, and in cases of complicated LUTS. 
Monopolar transurethral resection of the prostate (MTURP) 
has been the standard surgical procedure for men with 
prostate sizes of 30∼80 mL and bothersome moderate-to- 
severe LUTS secondary to BPO [3]. However, over the last 
decades, various innovative transurethral surgical proce-
dures have been developed to supplement or replace tran-
surethral resection of the prostate (TURP), including tran-
surethral microwave thermotherapy, transurethral needle 
ablation of the prostate, and laser prostatectomy. 
Laser prostatectomy has the advantage of involving rela-
tively less bleeding, as well as preventing transurethral re-
section (TUR) syndrome and capsule perforation during 
the procedure [4,5]. The most representative lasers cur-
rently in use are holmium:yttrium-aluminium-garnet (Ho: 
YAG), thulium:YAG (Tm:TAG), kalium-titanyl-phosphate 
(KTP), and semiconductor diodes (SCD). Photoselective 
vaporization of the prostate (PVP) using KTP or SCD lasers 
is one of the most popular laser-based surgical procedures 
performed to treat BPH, and leads to the immediate re-
moval of prostatic tissue, relief of BPO, and reduction of 
LUTS. PVP is considered to be a safe and effective proce-
dure and requires a relatively short training period [6,7].
As PVP has emerged as an alternative to MTURP in the 
treatment of BPH, several valuable randomized con-
trolled trials (RCTs) have compared the surgical efficacy 
and safety of MTURP and PVP [7-17]. Thus, we performed 
a systematic review and meta-analysis of these RCTs in or-
der to compare MTURP and PVP and to be able to provide 
the most up-to-date and reliable recommendations possible.
MATERIALS AND METHODS
1. Inclusion criteria
RCTs that met the following criteria were included: (1) 
a study design including a comparison of functional out-
comes and complications between PVP and MTURP in 
men treated for BPH; (2) the inclusion of accurate peri-
operative variables, including operative time, catheter-
ization time, and hospitalization time, as well as compli-
cation-related variables, including transfusion rate as well 
as rates of acute urinary retention, clot retention, and uri-
nary tract infection; (3) evaluation of long-term functional 
outcomes, including the International Prostate Symptom 
Score (IPSS) and the maximum flow rate (Qmax) parame-
ter; and (4) accessible full text of the study or abstract pre-
sented at a scientific conference.
2. Search strategy
A literature search was performed for all publications 
prior to December 31, 2015 in the PubMed and EMBASETM 
online databases. A cross-reference search of eligible ar-
ticles was carried out in order to identify additional studies 
not found by the computerized search. The following 
MeSH terms and keywords were used: prostatic hyper-
plasia, TUR of prostate, photoselective vaporization, TUR, 
prostate, BPH, and RCT. 
3. Data extraction
One researcher (D.H.K.) screened the titles and ab-
stracts that were identified using this search strategy. The 
other two researchers (J.Y.L. and K.S.C.) independently as-
sessed the full text of the papers to determine whether they 
met the inclusion criteria. The data entry procedure was 
designed to ensure the inclusion of the most relevant data, 
such as the author, year of publication, patient demo-
graphics, treatments, fertility rates, and the inclusion of a 
reference standard. Disagreements were resolved by dis-
cussion until a consensus was reached or by arbitration in-
volving another researcher (Y.D.C.).
4. Study quality assessment and publication bias
Once the final group of articles was agreed upon, two 
researchers (J.Y.L. and D.H.K.) independently assessed 
the quality of each article using the Cochrane risk of bias 
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Fig. 1. Flow diagram of screened, 
excluded, and analyzed publica-
tions. Based on the inclusion and 
exclusion criteria, 11 articles were 
excluded after a simple reading of 
the titles and abstracts of the arti-
cles, and two articles were exclu-
ded due to the patient population.
as a quality assessment tool for RCTs. This process in-
volved assigning a judgment of “yes,” “no,” or “unclear” 
for each domain in order to designate a low, high, or un-
clear risk of bias, respectively. If one domain or no domain 
was deemed “unclear” or “no,” the study was classified as 
having a low risk of bias. If four or more domains were 
deemed “unclear” or “no,” the study was classified as hav-
ing a high risk of bias. If two or three domains were 
deemed “unclear” or “no,” the study was classified as hav-
ing a moderate risk of bias [18]. Publication bias was ex-
amined using funnel plots and statistical results from the 
Begg and Mazumdar rank correlation test [19] and Egger’s 
regression test [20] for funnel plot asymmetry . In the ab-
sence of publication bias, this method assumes that the 
largest studies will be plotted near the average and that 
smaller studies will be spread evenly on both sides of the 
average, creating a roughly funnel-shaped distribution. 
Deviation from this shape can indicate publication bias. 
Quality assessment and investigation of publication bias 
were carried out using Review Manager 5 (RevMan 5.2.3; 
Cochrane Collaboration, Oxford, UK) and R (R version 
3.0.3; R Foundation for Statistical Computing, Vienna, 
Austria; http://www.r-project.org), with its metafor package.
5. Heterogeneity test
Heterogeneity among studies was evaluated using the 
Q statistic and Higgins’ I2 statistic [21]. Higgins’ I2 is used 
to measure a set of studies to identify the percentage of to-
tal variation due to heterogeneity rather than chance. 
Higgins’ I2 is calculated as follows:
I2= Q−df ×100%Q
where Q is Cochran’s heterogeneity statistic and df re-
fers to the degrees of freedom.
An I2 greater than 50% is considered to represent sub-
stantial heterogeneity. For the Q statistic, heterogeneity 
was deemed to be significant if the p-value was ＜0.10 
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Table 1. Studies included in this meta-analysis
Study Year Techniques
Follow-up 
duration 
(mo)
Inclusion criteria
Bias 
riskaProstate 
size (mL)
Anticoag
ulation
Age 
(yr)
Minimal 
IPSS
Maximal 
Qmax
Horasanli et al [8] 2008 MTURP PVP-80 W 6 70∼100 N/A N/A 7 15 Low
Bouchier-Hayes et al [7] 2010 MTURP PVP-80 W 12 N/A Excluded ＞50 12 15 Low
Al-Ansari et al [9] 2010 MTURP PVP-120 W 36 ＜100 Excluded N/A 16 15 Low
Capitán et al [10] 2011 MTURP PVP-120 W 24 ＜80 Included N/A 15 15 Low
Lukacs et al [11] 2012 MTURP PVP-120 W 12 ＜80 Excluded N/A 12 12 Low
Mohanty et al [12] 2012 MTURP PVP-80 W 12 20∼80 N/A ＞50 7 15 Moderate
Pereira-Correia et al [13] 2012 MTURP
(mannitol)
PVP-120 W 24 ＜60 N/A N/A N/A N/A Low
Kumar et al [14] 2013 MTURP PVP-120 W 12 20∼80 Excluded ＞50 7 15 Low
Xue et al [15] 2013 MTURP PVP-120 W 36 ＜100 N/A N/A 15 15 Moderate
Telli et al [16] 2015 MTURP PVP-120 W 24 ＜80 N/A N/A 7 15 Low
Cetinkaya et al [17] 2015 MTURP PVP-120 W 3 ＜80 Included N/A 15 15 Low
IPSS: International Prostate Symptom Score, Qmax: maximum flow rate, MTURP: monopolar transurethral resection of the 
prostate, PVP: photoselective vaporization of the prostate, N/A: not available.
aQuality assessment was based on using Cochrane’s risk of bias as a quality assessment tool for randomized controlled 
trials. If four or more domains were deemed “unclear” or “no,” the study was classified as having a high risk of bias. If 
two or three domains were deemed “unclear” or “no,” the study was classified as having a moderate risk of bias.
[22]. When evidence of heterogeneity was found, the data 
were analyzed using a random-effects model to obtain a 
summary estimate for the test sensitivity along with 95% 
confidence intervals (CIs). Studies in which positive re-
sults were confirmed were analyzed using pooled specif-
icity with 95% CIs. In addition, Galbraith’s radial plots 
[23] were performed to evaluate heterogeneity.
6. Statistical analysis
When a significant Q-test indicated heterogeneity across 
studies (p＜0.10 or I2＞50%), a random-effects model was 
used for the meta-analysis; otherwise, a fixed-effects mod-
el was employed [24]. The meta-analysis of comparable 
data was carried out using Review Manager 5.3 and R, us-
ing its meta and metafor packages.
RESULTS
1. Eligible studies
Our database search found 40 articles that could have 
potentially been included in the meta-analysis. Based on 
the inclusion and exclusion criteria, 11 articles were ex-
cluded after a simple reading of the titles and abstracts of 
the articles, and two articles were excluded due to the pa-
tient population. Ultimately, 11 articles were included in 
the analysis of PVP versus MTURP (Fig. 1) [7-17]. The stud-
ies that were included are summarized in Table 1.
2. Quality assessment 
Fig. 2 presents the details of quality assessment, as 
measured by the Cochrane Collaboration risk-of-bias tool. 
Two trials exhibited a moderate risk of bias for all quality 
criteria, while the others were classified as having a low 
risk of bias (Table 1). The most common risk factor for 
quality assessment was the risk of insufficient information 
concerning allocation concealment, followed by con-
cerns involving random sequence generation. Most re-
cently published studies exhibited a low risk with regard 
to quality assessment.
3. Publication bias
The Begg and Mazumdar rank correlation tests [19] in 
each analysis showed no evidence of publication bias in 
the present meta-analysis (operation time, p=0.275; cath-
eterization time, p=0.239; hospitalization time, p=0.469; 
transfusion rate, p=0.283; acute urinary retention, p= 
0.773; clot retention, p=0.333; urinary tract infection, 
p=0.399; bladder neck contracture, p=1.000; urethral 
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Fig. 2. Methodological quality graph. Two researchers’ judg-
ments about each methodological quality item are presented as 
percentages across all included studies. Two trials exhibited a 
moderate risk of bias for all quality criteria and all others were 
classified as having a low risk of bias.
stricture, p=0.469; IPSS, p=0.719; Qmax, p=1.000). 
Egger’s regression intercept tests [20] revealed that cathe-
terization time exhibited publication bias, whereas all oth-
er variables showed no evidence of publication bias 
(operation time, p=0.351; catheterization time, p＜0.001; 
hospitalization time, p=0.215; transfusion rate, p=0.233; 
acute urinary retention, p=0.431; clot retention, p=0.555; 
urinary tract infection, p=0.237; bladder neck contrac-
ture, p=0.923; urethral stricture, p=0.584; IPSS, p=0.925; 
Qmax, p=0.731). Funnel plots from these meta-analyses 
are shown in Fig. 3.
4. Heterogeneity assessment
Forest plots are shown in Fig. 4∼7. A heterogeneity test 
showed that notable degrees of heterogeneity were de-
tected in the analyses for operation time, catheterization 
time, and hospitalization time (Fig. 4); thus, random- ef-
fects models were used to further assess these variables. 
However, no significant heterogeneity was found in the 
other analyses, so fixed-effect models were applied. In 
Galbraith’s radial plots, no variables demonstrated hetero-
geneity after the selection of effect models for each varia-
ble (Fig. 8).
5. Results from forest plots
In a meta-analysis of operation time between PVP and 
MTURP, the forest plot using the random effect model 
showed a mean difference of 12.89 (95% CI=7.09∼
18.70, p＜0.001), favoring MTURP (Fig. 4A). However, 
the mean differences for catheterization and hospital-
ization time were −1.39 (95% CI=−1.83∼−0.95, p＜ 
0.001) and −2.21 (95% CI=−2.73∼−1.69, p＜0.001), 
respectively, favoring PVP (Fig. 4A, 4B). PVP was found to 
be superior to MTURP with regard to the transfusion rate 
(odds ratio [OR]=0.17, 95% CI=0.08∼0.37, p＜0.001) 
and clot retention (OR=0.10, 95% CI=0.03∼0.27, p
＜0.001) (Fig. 5A, 5C); however, no statistically significant 
differences were found regarding acute urinary retention 
and urinary tract infection (Fig. 5B, 5D). The long-term 
complications of bladder neck contracture and urethral 
stricture showed no statistically significant differences be-
tween PVP and MTURP (Fig. 6). Long-term functional out-
comes, including IPSS and Qmax, also demonstrated no 
statistically significant differences between PVP and 
MTURP (Fig. 7). 
DISCUSSION
Several meta-analyses comparing PVP and MTURP 
have already been published [25-27]. These meta-analy-
ses have found that MTURP was characterized by a shorter 
operative time, while PVP showed shorter catheterization 
and hospitalization times. Bleeding-related complications 
and TUR syndrome occurred more frequently in MTURP. 
In terms of voiding efficacy, the effects of the two proce-
dures were similar. The results of the present meta-analy-
sis are not different from those reported in previous stud-
ies, but our study does have some advantages compared to 
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Fig. 3. Funnel plots. Egger’s regression intercept tests demonstrated that catheterization time showed evidence of publication bias (p＜
0.001), whereas the other variables had no evidence of publication bias. (A) Operation time. (B) Hospitalization time. (C) Catheterization
time. (D) Transfusion rate. (E) Acute urinary retention. (F) Clot retention. (G) Urinary tract infection. (H) Bladder neck contracture. (I) 
Urethral stricture. (J) International Prostate Symptom Score. (K) Maximum flow rate. SE: standard error, MD: mean difference, OR: odds
ratio.
previous studies. First, some of those analyses included 
case-control studies, while our meta-analysis included on-
ly RCTs. Second, at least three years have passed since the 
most recent meta-analysis, and we were able to include 
additional high-quality RCTs that have been published 
since. Thus, the present meta-analysis can provide the 
most up-to-date and reliable recommendations that have 
yet been published.
As the elderly population has increased, the prevalence 
of typical age-related male diseases, such as male LUTS 
secondary to BPH, has increased [28]. The effectiveness of 
medical treatment for this conditions is relatively high, but 
patients need to undergo surgery in cases of renal in-
sufficiency secondary to BPH, recurrent urinary tract in-
fections (UTIs), gross hematuria due to BPH or bladder 
stones, and LUTS refractory to other therapies [29]. MTURP 
has demonstrated improved long-term efficacy and safety, 
and has emerged as the gold standard surgery in patients 
with prostate sizes under 80 mL and moderate-to-severe 
LUTS secondary to BPO [3]. However, TURP-related mor-
bidities such as TUR syndrome and bleeding still pose 
considerable challenges. For this reason, alternative pro-
cedures have been developed that show similar levels of 
efficacy but lower complication rates. Laser procedures, 
such as Holmium laser enucleation of the prostate (HoLEP) 
and PVP, are the most representative alternatives to 
MTURP. A meta-analysis by Tan et al [30] found that 
HoLEP showed a similar voiding efficiency and a lower 
complication rate than MTURP. In other recent meta-anal-
yses, the IPSS and Qmax scores after one year among pa-
tients treated with HoLEP were slightly better than among 
patients treated with MTURP [31,32]. However, HoLEP 
has the disadvantage of requiring a substantial amount of 
training due to the technical challenges that it poses, and 
it can be dangerous for unskilled surgeons to perform this 
procedure [7]. PVP is also one of the most popular alter-
native treatments. The main advantage of PVP is that it is 
technically simpler than HoLEP, with a relatively straight-
forward learning curve [6,7]. However, HoLEP can be 
safely used to treat larger prostates that would otherwise 
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Fig. 4. Forest plots comparing operation time (A), catheterization time (B), and hospitalization time between PVP and MTURP (C). With
regard to operative time, the forest plot using the random effect model showed a MD of 12.89 (95% CI=7.09∼18.70, p＜0.001) in 
favor of MTURP. However, the MDs for catheterization and hospitalization time were −1.39 (95% CI=−1.83∼−0.95, p＜0.001)
and −2.21 (95% CI=−2.73∼−1.69, p＜0.001), respectively, in favor of PVP. PVP: photoselective vaporization of the prostate, 
MTURP: monopolar transurethral resection of the prostate, SD: standard deviation, CI: confidence interval, MD: mean difference, W:
weight. 
be treated through open prostatectomy. Although we only 
compared PVP and MTURP in the present meta-analysis, 
HoLEP is another promising alternative, and we suggest 
that meta-analyses comparing MTURP, PVP, and HoLEP 
are needed in the future.
When analyzing transurethral prostate surgical proce-
dures, voiding parameters should be considered the most 
important treatment outcomes. In this meta-analysis, no 
significant differences were found between PVP and 
MTURB in IPSS and Qmax at one year of follow-up. The 
long-term data regarding PVP remains insufficient, making 
it impossible to analyze follow-up results over a period lon-
ger than one year. Further studies should be performed to 
evaluate the long-term efficacy of PVP in terms of voiding 
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Fig. 5. Forest plots of transfusion rates (A), acute urinary retention (B), clot retention (C), and urinary tract infection comparing PVP and
MTURP (D). Superior results were found for PVP regarding transfusion rates (OR=0.17, 95% CI=0.08∼0.37, p＜0.001) and clot 
retention (OR=0.10, 95% CI=0.03∼0.27, p＜0.001), but no statistically significant differences were found for acute urinary retention 
and urinary tract infection. PVP: photoselective vaporization of the prostate, MTURP: monopolar transurethral resection of the prostate,
OR: odds ratio, CI: confidence interval, W: weight.
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Fig. 6. Forest plots comparing bladder neck contracture (A) and urethral stricture between PVP and MTURP (B). No statistically 
significant differences were found. PVP: photoselective vaporization of the prostate, MTURP: monopolar transurethral resection of the
prostate, OR: odds ratio, CI: confidence interval, W: weight.
parameters.
Regarding perioperative outcomes, the mean operative 
time was significantly shorter, by approximately 13 mi-
nutes, in the MTURP group. Various explanations of this 
finding may be proposed: the surgeons may not have been 
experienced with PVP; the laser may not have provided 
enough energy or power to the prostatic tissue; or the PVP 
laser energy absorption in water may be minimal, result-
ing in prolonged operations [33]. However, the mean op-
erative time of PVP can be substantially reduced by im-
proving the surgeon’s overall faculties, technical skills, 
and confidence. Furthermore, recent studies on PVP using 
lasers with more than 120 W of power (160 W and 180 W) 
[34-36] have been conducted with the goal of reducing the 
operative time of PVP. In contrast, the catheterization and 
hospitalization times were significantly shorter in the PVP 
group. The discharge was especially faster in the subgroup 
of PVP patients more than two days compared to the sub-
group of MTURP patients. The catheterization and hospi-
talization time are important factors affecting patients’ 
quality of life, so this result indicates a major advantage of 
PVP. 
It is well-known that KTP lasers are strongly absorbed by 
hemoglobin, resulting in excellent homeostasis [37]. For 
this reason, bleeding-related complications occurred more 
frequently in the MTURP group, as well as higher trans-
fusion and clot retention rates. This finding indirectly sup-
ports the results of studies evaluating PVP in patients tak-
ing anticoagulants [38,39]. No significant differences be-
tween the groups were found with regard to either early 
postoperative complications, including acute urinary re-
tention and UTIs, or late complications, including bladder 
neck contracture and urethral stricture. TUR syndrome 
does not occur in PVP because saline is used as the fluid 
medium instead of glycine, and it was therefore impos-
sible to perform a meta-analysis for TUR syndrome. The 
total TUR syndrome rate in the MTURP group was 1.7% 
(7/409). Combining all of these results regarding efficacy 
and safety, it seems reasonable for PVP to be performed as 
an alternative surgical treatment for treating male LUTS 
secondary to BPH, although long-term follow-up remains 
essential in the future.
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Fig. 7. Forest plots comparing long-term functional outcomes, including IPSS (A) and Qmax (B). No differences were found between PVP
and MTURP. IPSS: International Prostate Symptom Score, PVP: photoselective vaporization of the prostate, MTURP: monopolar 
transurethral resection of the prostate, SD: standard deviation, MD: mean difference, CI: confidence interval, W: weight, Qmax: 
maximum flow rate.
Most of the studies we analyzed used GreenLightTM la-
sers (KTP, wavelength 532 nm) for PVP, but SCD lasers 
were used in one study [17]. The SCD laser uses the wave-
length (980 nm) that has the highest absorption for hemo-
globin and water, providing both hemostatic and ablative 
properties [17]. The GreenLightTM laser power was also 
not uniform (80 W or 120 W) across the studies we an-
alyzed. These discrepancies may theoretically be a source 
of bias, but do not think that it was significant because this 
meta-analysis was focused on PVP overall, rather than on 
laser type or power. As stated above, studies are now eval-
uating PVP performed with lasers with more than 120 W 
of power (160 W and 180 W) [34-36], but it is too early to 
present an informed discussion of the efficacy and safety 
of high-energy PVP. These issues must be addressed in fu-
ture comparative studies.
One limitation of our meta-analysis is that we did not as-
sess sexual complications, such as erectile dysfunction 
and ejaculatory disorders. So far, an insufficient number of 
RCTs have evaluated sexual complications. Additionally, 
our study was also susceptible to some degree of pub-
lication bias. However, Sutton et al [40] reviewed 48 ar-
ticles from the Cochrane Database of Systematic Reviews 
and showed that publication bias and related biases were 
common within their sample of meta-analyses, and found 
that these biases did not affect the conclusions in most 
cases. Despite these limitations, our study is a valuable 
meta-analysis because it spans studies performed over a 
longer period than previous analyses and provides more 
up-to-date and reliable evidence.
CONCLUSIONS
In our meta-analysis of functional outcomes and com-
plications following PVP and MTURP, voiding efficiency 
at one year of follow-up was similar between these two 
procedures. The operative time was significantly shorter 
for MTURP, while the catheterization and hospitalization 
times were significantly shorter for PVP. Bleeding-related 
complications occurred more frequently in MTURP. 
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Fig. 8. Galbraith’s radial plots. Most variables demonstrated little heterogeneity after selecting the effect models for each variable. (A) 
Operation time. (B) Hospitalization time. (C) Catheterization time. (D) Transfusion rate. (E) Acute urinary retention. (F) Clot retention. 
(G) Urinary tract infection. (H) Bladder neck contracture. (I) Urethral stricture. (J) International Prostate Symptom Score. (K) Maximum 
flow rate.
Based on these findings, we believe that PVP can be per-
formed as an alternative surgical procedure for treating 
male LUTS secondary to BPH.
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